Cancer treatment delays surge across US as doctor warns system ‘needs fixing immediately’

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions. Legal Statement. Mutual Fund and ETF data provided by LSEG. Dr. Loren Rourke, a Texas-based board-certified breast cancer surgeon, author and speaker, confirmed research has suggested that glucagon-like peptide-1 medications may be associated with a lower risk of cancer recurrence. Wait times between a cancer diagnosis and the start of treatment grew by nearly two weeks over the past decade in the U.S., according to a recent study published in JAMA Surgery. Researchers from the University of California, Los Angeles and Massachusetts General Hospital analyzed national data from more than two million patients diagnosed between January 2012 and December 2023. The study tracked adults with early to locally advanced stages of six common cancers (breast, colon, lung, pancreatic, stomach and esophageal) who received surgery as part of their initial care. WHERE YOU LIVE COULD SHAPE YOUR RISK OF CANCER MORTALITY, STUD